Annotation Detail
Information
- Associated Genes
- AKT3
- Associated Variants
-
AKT3 OVEREXPRESSION
AKT3 OVEREXPRESSION - Associated Disease
- melanoma
- Source Database
- CIViC Evidence
- Description
- An in vitro study of M229 (a human melanoma cell line) endogenously expressing wildtype AKT3 and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells induced to stably over-express AKT3 (via viral transduction of additional copies of wild type AKT3) were significantly more resistant to BRAF inhibition by vemurafenib than cells transduced with empty vectors (30% vs 20% survival, p = .0064).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/6261
- Gene URL
- https://civic.genome.wustl.edu/links/genes/7936
- Variant URL
- https://civic.genome.wustl.edu/links/variants/1301
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Melanoma
- Evidence Direction
- Supports
- Drug
- Vemurafenib
- Evidence Level
- D
- Clinical Significance
- Resistance
- Pubmed
- 24265155
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Vemurafenib | Resitance or Non-Reponse | true |